Gallium Ga 68-labeled PSMA-11 PET / MR in Diagnosing Patients with Recurrent Prostate Cancer
- Biopsy proven adenocarcinoma of the prostate
- Initially treated with definitive local therapy (surgery and radiation therapy are the most common treatments, but other treatments are also eligible)
- For patients initially treated with surgery, radiation therapy, brachytherapy, or cryotherapy: * PSA >= 0.2 ng/mL in at least two consecutive tests within 6 months of date of consent for patients ** Note: The most recent PSA value must be within 6 weeks of consent
- For patients who have received additional treatment in the recurrent or metastatic setting: * PSA >= 0.2 ng/ml above the most recent therapy nadir
- Patient must be able to tolerate PET/CT or PET/MR imaging
- Patient with claustrophobia that would preclude PET/CT or PET/MR imaging or other contraindications to CT imaging
I. To provide clinical access to gallium Ga 68-labeled PSMA-11 (68Ga-HBED-iPSMA) PET at Memorial Sloan Kettering Cancer Center.
Patients receive gallium Ga 68-labeled PSMA-11 intravenously (IV) and after 60-90 minutes, undergo PET/MR or PET/computed tomography (CT) over 30-45 minutes.
After completion of study, patients are followed up every 3-4 months for at least 2 years.
Trial Phase Phase II
Trial Type Diagnostic
Memorial Sloan Kettering Cancer Center
- Primary ID 16-306
- Secondary IDs NCI-2017-01348
- Clinicaltrials.gov ID NCT03204123